local_hospital

Centre Hospitalier Dr Jean Eric Techer

Address
1601 Boulevard Des Justes, Bp 339, 62100 Calais, France

Centre Hospitalier Dr Jean Eric Techer - Multidisciplinary Research Center

Centre Hospitalier Dr Jean Eric Techer is a comprehensive medical research facility conducting diverse clinical investigations across multiple therapeutic areas. The center demonstrates expertise in both oncology and critical care medicine, with particular emphasis on innovative treatment combinations and patient-centered approaches to complex diseases.

  • Advanced oncology research including non-small cell lung cancer, gastroesophageal malignancies, and immunotherapy combinations with radiation and chemotherapy
  • Critical care and septic shock management, focusing on cardiovascular complications and renal protection strategies
  • Neurological disorders including multiple sclerosis and Alzheimer's disease with novel therapeutic interventions
  • Cardiovascular and cerebrovascular disease prevention, particularly in post-stroke and atherosclerotic populations

The center's research portfolio reflects a commitment to addressing high-impact medical conditions through randomized controlled trials and proof-of-concept studies. Their work spans from immunotherapy combinations in advanced cancers to innovative approaches in septic shock with hypercontractility, demonstrating particular interest in precision medicine approaches for vulnerable patient populations including frail cancer patients and critically ill intensive care patients.

Site Overview

assignment
12
connected trials
corporate_fare
9
sponsors
science
32
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
12
Total trials linked
Highly Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 7 therapeutic areas and 15 of 32 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
9
Sponsors (total)
9
Active sponsors
8

Sponsor Network

Top 8 by active trials.

lock +7 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +2 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
12
Outperforms 75% of sites
public
Therapeutic diversity
7areas
Outperforms 79% of sites
groups
Sponsor diversity
9sponsors
Outperforms 76% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centre Hospitalier Dr Jean Eric Techer

lock Showing 1 of 12 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects with Moderate to Severe Plaque PsoriasisBristol-Myers Squibb Services Unlimited CompanyPhase IIIRecruitingMay 2021

IMP list

lock Showing 1 of 32 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Carboplatin2Unknown2019-03-212025-11-28

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.